Roderick de Greef - 16 Nov 2021 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Signature
/s/ Roderick de Greef
Issuer symbol
BLFS
Transactions as of
16 Nov 2021
Net transactions value
-$1,072,540
Form type
4
Filing time
18 Nov 2021, 19:01:51 UTC
Previous filing
27 Oct 2021
Next filing
30 Dec 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Sale $359,730 -7,000 -5.6% $51.39 117,333 16 Nov 2021 Direct F1, F2
transaction BLFS Common Stock Sale $357,560 -7,000 -6% $51.08 110,333 17 Nov 2021 Direct F1, F3
transaction BLFS Common Stock Sale $355,250 -7,000 -6.3% $50.75 103,333 18 Nov 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.15 to $51.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.10 to $51.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.